Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

被引:17
|
作者
Li, Wei-ming [1 ]
Zhao, Yi-fan [1 ]
Zhu, Guo-fu [1 ]
Peng, Wen-hui [1 ]
Zhu, Meng-yun [1 ]
Yu, Xue-jing [1 ]
Chen, Wei [1 ]
Xu, Da-chun [1 ]
Xu, Ya-wei [1 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cardiol, Sch Med, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
cardiac hypertrophy; dual specific phosphatase 12; c-Jun N-terminal kinase (JNK); signalling pathway; SP600125; N-TERMINAL KINASE; HEART-FAILURE; ACTIVATION; REGULATORS; CARDIOMYOPATHY; IDENTIFICATION; APOPTOSIS; REVEALS; BINDING; ERK1/2;
D O I
10.1042/CS20160664
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase (DUSP) family, which is characterized by its DUSP activity to dephosphorylate both tyrosine and serine/threonine residues on one substrate. Some DUSPs have been identified as being involved in the regulation of cardiac hypertrophy. However, the role of DUSP12 during pathological cardiac hypertrophy is still unclear. In the present study, we observed a significant decrease in DUSP12 expression in hypertrophic hearts and cardiomyocytes. Using a genetic loss-of-function murine model, we demonstrated that DUSP12 deficiency apparently aggravated pressure overload-induced cardiac hypertrophy and fibrosis as well as impaired cardiac function, whereas cardiac-specific overexpression of DUPS12 was capable of reversing this hypertrophic and fibrotic phenotype and improving contractile function. Furthermore, we demonstrated that JNK1/2 activity but neither ERK1/2 nor p38 activity was increased in the DUSP12 deficient group and decreased in the DUSP12 overexpression group both in vitro and in vivo under hypertrophic stress conditions. Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice. DUSP12 protects against pathological cardiac hypertrophy and related pathologies. This regulatory role of DUSP12 is primarily through c-Jun N-terminal kinase (JNK) inhibition. DUSP12 could be a promising therapeutic target of pathological cardiac hypertrophy. DUSP12 is down-regulated in hypertrophic hearts. An absence of DUSP12 aggravated cardiac hypertrophy, whereas cardiomyocyte-specific DUSP12 overexpression can alleviate this hypertrophic phenotype with improved cardiac function. Further study demonstrated that DUSP12 inhibited JNK activity to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 50 条
  • [41] Short-term caloric restriction ameliorates cardiac hypertrophy and oxidative stress in mice with chronic pressure overload
    Furumori, Akiko
    Kobara, Miyuki
    Matsumura, Mihoko
    Shiraishi, Tatsuya
    Kitamura, Miho
    Noda, Kazuki
    Toba, Hiroe
    Nakata, Tetsuo
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (07) : S162 - S162
  • [42] Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy
    Zhu, Xuehai
    Fang, Jing
    Gong, Jun
    Guo, Jun-Hong
    Zhao, Guang-Nian
    Ji, Yan-Xiao
    Liu, Hong-Yun
    Wei, Xiang
    Li, Hongliang
    HYPERTENSION, 2016, 67 (05) : 866 - 877
  • [43] Growth Arrest-Specific 6 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy
    Zhao, Yi-fan
    Xu, Da-chun
    Zhu, Guo-fu
    Zhu, Meng-yun
    Tang, Kai
    Li, Wei-ming
    Xu, Ya-wei
    HYPERTENSION, 2016, 67 (01) : 118 - 129
  • [44] Role of phosphatase and tensin homologue (PTEN) in adrenal medulla hypertrophy after chronic cardiac pressure overload in mice
    Albarran-Juarez, J.
    Gilsbach, R.
    Schneider, J.
    Hein, L.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 : 56 - 56
  • [45] Predictions of hypertrophy and its regression in response to pressure overload
    Kyoko Yoshida
    Andrew D. McCulloch
    Jeffrey H. Omens
    Jeffrey W. Holmes
    Biomechanics and Modeling in Mechanobiology, 2020, 19 : 1079 - 1089
  • [46] Cardiac-specific Deletion of Protein Tyrosine Phosphatase 1B Exacerbates Pressure Overload-induced Hypertrophy and Heart Failure in Mice
    Coulis, Gerald
    Bergeron, Alexandre
    Shi, Yanfen
    Labbe, David
    Tremblay, Michel
    Karsenty, Gerard
    Boivin, Benoit
    CIRCULATION RESEARCH, 2016, 119
  • [47] Predictions of hypertrophy and its regression in response to pressure overload
    Yoshida, Kyoko
    McCulloch, Andrew D.
    Omens, Jeffrey H.
    Holmes, Jeffrey W.
    BIOMECHANICS AND MODELING IN MECHANOBIOLOGY, 2020, 19 (03) : 1079 - 1089
  • [48] Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome
    He, Wenxiu
    Wei, Jiahe
    Liu, Xing
    Zhang, Zhongyin
    Huang, Rongjie
    Jiang, Zhiyuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [49] Loss of talin in cardiac fibroblasts results in augmented ventricular cardiomyocyte hypertrophy in response to pressure overload
    Noll, Natalie A.
    Riley, Lance A.
    Moore, Christy S.
    Zhong, Lin
    Bersi, Mathew R.
    West, James D.
    Zent, Roy
    Merryman, W. David
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2022, 322 (05): : H857 - H866
  • [50] Bone Marrow Age, Not Myocardial Age, Determines Cardiac Myocyte Hypertrophy in Response to Pressure Overload
    Sopko, Nikolai
    Becker, Mitchell
    Dong, Feng
    Popovick, Zoran
    Drinko, Jeanne
    Penn, Marc
    CIRCULATION RESEARCH, 2009, 105 (07) : E25 - E26